Bolt Biotherapeutics Inc Forecast, price target & analysts
Bolt Biotherapeutics Inc Target price 2026 - Analyst rating & recommendation
Bolt Biotherapeutics Inc Classifications & Recommendation
Bolt Biotherapeutics Inc Price Target
| Target Price | $6.12 |
| Price | $3.45 |
| Potential |
77.39%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Bolt Biotherapeutics Inc 2027 .
The average Bolt Biotherapeutics Inc target price is $6.12.
This is
77.39%
register free of charge
$7.35
113.04%
register free of charge
$5.05
46.38%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Bolt Biotherapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bolt Biotherapeutics Inc stock has an average upside potential 2027 of
77.39%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.70 | 0.20 |
| 0.13% | 97.35% | |
| EBITDA Margin | -432.99% | -68,019.00% |
| 49.90% | 15,609.25% | |
| Net Margin | -433.51% | -22,539.19% |
| 47.19% | 5,099.27% |
6 Analysts have issued a sales forecast Bolt Biotherapeutics Inc 2026 . The average Bolt Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Bolt Biotherapeutics Inc EBITDA forecast 2026. The average Bolt Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-33.3m | 49.83% |
|---|---|---|
| 2026 |
$-139m
316.19%
unlock
|
|
EBITDA Margin
| 2025 | -432.99% | 49.90% |
|---|---|---|
| 2026 |
-68,019.00%
15,609.25%
unlock
|
|
6 Bolt Biotherapeutics Inc Analysts have issued a net profit forecast 2026. The average Bolt Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -17.85 | -23.82 |
| 46.01% | 33.45% | |
| P/E | negative | |
| EV/Sales | negative |
6 Analysts have issued a Bolt Biotherapeutics Inc forecast for earnings per share. The average Bolt Biotherapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Bolt Biotherapeutics Inc...
Current Bolt Biotherapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Rodman & Renshaw |
Locked
➜
Locked
|
Locked | May 29 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 28 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2026 |
| Lake Street |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | May 20 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | May 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Rodman & Renshaw:
Locked
➜
Locked
|
May 29 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2026 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Aug 15 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
May 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 25 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
